Market Mover: Repligen (RGEN) Climbs at Midday June 23

Equities Staff  |

Repligen Corp. (NASDAQ: RGEN) shares moved 5.07%, or $7.535 per share, as on 12:05:27 est today. Since opening the day at $149.71, 125,836 shares of Repligen have been traded today and the stock has traded between $156.82 and $147.79.  

Already the company has a YTD change of 43.85%.

Repligen is set to release earnings on 2022-07-26.

For technical charts, analysis, and more on Repligen visit the company profile.

About Repligen Corp.

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Its primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of its manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. it has sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

To get more information on Repligen Corp. and to follow the company's latest updates, you can visit the company's profile page here: Repligen Corp.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content